第二代减毒活登革疫苗的临床开发与监管考量要点
本文总结第二代减毒活登革疫苗临床开发和监管审查中需考虑的要点。基于世界卫生组织2012年减毒四价登革疫苗指南及后续两项平行3期试验的效力和长期随访数据,指出四价登革疫苗存在复杂性,包括疫苗可能增加特定亚人群登革病发病风险的担忧,旨在为疫苗开发者提供试验设计参考并促进监管审查以支持更广泛的公共卫生推荐。
要点
- 第二代减毒活登革疫苗的临床开发需参考世界卫生组织2012年减毒四价登革疫苗质量、安全性和效力指南。
- 两项平行3期试验的效力和长期随访数据显示四价登革疫苗存在复杂性,包括特定亚人群发病风险增加的担忧。
- 本文总结临床与监管考量要点,旨在指导疫苗开发者试验设计并促进监管审查以支持更广泛公共卫生推荐。
核心结论
- 本报告总结了临床和监管考量要点,可能指导疫苗开发者试验设计的某些方面,并促进监管审查,以支持第二代登革疫苗更广泛的公共卫生推荐。
研究设计与样本
- 本文为总结性报告,基于世界卫生组织2012年减毒四价登革疫苗指南及后续两项平行3期试验的效力和长期随访数据,梳理第二代减毒活登革疫苗临床开发与监管考量要点。
主要发现
- 两项平行3期试验的效力和长期随访数据(疫苗于2015年12月获批)的发现和解释凸显了四价登革疫苗的关键复杂性,包括疫苗接种可能增加特定亚人群登革病发病风险的担忧。
关键数值与推荐
- 世界卫生组织于2012年发布了减毒四价登革疫苗质量、安全性和效力指南。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The findings and interpretation of the results from these trials released both before and after licensure have highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical and regulatory points for consideration that may guide vaccine developers on some aspects of trial design and facilitate regulatory review to enable broader public health recommendations for second-generation dengue vaccines.
引用
- Vannice KS, Wilder-Smith A, Barrett ADT, et al. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine. 2018. PMID: 29525283. doi:10.1016/j.vaccine.2018.02.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。